EPIDEMIOLOGICAL AND CLINICAL VALUE OF OCCULT HBV INFECTION


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Occult HBV infection is characterized by the persistence of hepatitis B virus in the liver and/or blood the absence of HBsAg. The data on the prevalence of the infection in different world regions and populations vary over a wide range. The mechanisms of occult infection are determined by the occurrence of individual virus mutations, by a number of epigenetic factors, but mainly by immunological control patterns. Since HBsAg is a basic marker and generally the only one for detection of HBV infection in real clinical practice, occult HBV infection is a real threat to virus spread in the population and to hepatitis B activation in immunosuppressed patients.

About the authors

V A ALESHKIN

G.N. Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology, Russian Federal Service for Supervision of ConsumerRights Protection and Human Welfare

Email: info@gabrich.com <mailto:info@gabrich.com>
G.N. Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology, Russian Federal Service for Supervision of ConsumerRights Protection and Human Welfare

M L ZUBKIN

G.N. Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology, Russian Federal Service for Supervision of ConsumerRights Protection and Human Welfare

Email: m-zubkin@yandex.ru <mailto:m-zubkin@yandex.ru>
G.N. Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology, Russian Federal Service for Supervision of ConsumerRights Protection and Human Welfare

E P SELKOVA

G.N. Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology, Russian Federal Service for Supervision of ConsumerRights Protection and Human Welfare

Email: selkova.e@mail.ru <mailto:selkova.e@mail.ru>
G.N. Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology, Russian Federal Service for Supervision of ConsumerRights Protection and Human Welfare

V I CHERVINKO

Institute for Postgraduate Training of Physicians, P.V. Mandryka Medical Training and Research Clinical Center, Ministry of Defense of theRussian Federation

Email: dok534@yandex.ru <mailto:dok534@yandex.ru>
Institute for Postgraduate Training of Physicians, P.V. Mandryka Medical Training and Research Clinical Center, Ministry of Defense of theRussian Federation

A P SUSLOV

Honorary Academician N.F Gamaleya Federal Research Center for Epidemiology and Microbiology, Ministry of Health of Russia

Email: Anatoly.Suslov@nearmedic.ru <mailto:Anatoly.Suslov@nearmedic.ru>
Honorary Academician N.F Gamaleya Federal Research Center for Epidemiology and Microbiology, Ministry of Health of Russia

YU V OVCHINNIKOV

P.V. Mandryka Medical Training and Research Clinical Center

Email: ovchinnikov.munkc@mail.ru <mailto:ovchinnikov.munkc@mail.ru>
P.V. Mandryka Medical Training and Research Clinical Center

L V YAROSH

Honorary Academician N.F Gamaleya Federal Research Center for Epidemiology and Microbiology, Ministry of Health of Russia

Email: yarosh.lyudmila@imbox.ru
Honorary Academician N.F Gamaleya Federal Research Center for Epidemiology and Microbiology, Ministry of Health of Russia

A I USHAKOVA

City Clinical Hospital Fifty-Two, Moscow Healthcare Department

Email: anzhela_52@imbox.ru <mailto:anzhela_52@imbox.ru>
City Clinical Hospital Fifty-Two, Moscow Healthcare Department

V G NOVOZHENOV

Institute for Postgraduate Training of Physicians, P.V. Mandryka Medical Training and Research Clinical Center, Ministry of Defense of theRussian Federation

Email: nhandrew@mail.ru <mailto:nhandrew@mail.ru>
Institute for Postgraduate Training of Physicians, P.V. Mandryka Medical Training and Research Clinical Center, Ministry of Defense of theRussian Federation

Т А SEMENENKO

Honorary Academician N.F Gamaleya Federal Research Center for Epidemiology and Microbiology, Ministry of Health of Russia

Email: semenenko@gamaleya.org <mailto:semenenko@gamaleya.org>
Honorary Academician N.F Gamaleya Federal Research Center for Epidemiology and Microbiology, Ministry of Health of Russia

References

  1. EASL. Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. J. Hepatol. 2012; 57: 167-185.
  2. EASL. Clinical Practice Guidelines: management of chronic hepatitis B. J. Hepatol. 2009; 50: 227-242.
  3. Raimondo G., Allain J.P., Brunetto M.R., Buendia M.A., ChenD.S., Colombo M., Craxi A., Donato F., Ferrari C., Gaeta G.B., Gerlich W.H., Levrero M., Locarnini S., Michalak T., Mondelli M.U., Pawlotsky J.M., Pollicino T., Prati D., Puoti M., Samuel D., Shouval D., Smedile A., Squadrito G., Trepo C., Villa E., Will H., Zanetti A.R., Zoulim F. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J. Hepatol. 2008; 49: 652-657.
  4. Апросина З.Г., Серов В.В. Патогенез хронического гепатита В. Архив патологии 2001; 2: 58-62.
  5. Ивашкин В.Т., Герман Е.Н., Маевская М.В. Скрытая инфекция вирусом гепатита В. РЖГГК 2008; 18 (2): 4-9.
  6. Chemin I., Vermot-Desroches C., Baginski I., Saurin J.C., Laurent F., Zoulim F., Bernaud J., Lamelin J.P., Hantz O., Rigal D., Trepo С. Selective detection of human hepatitis B virus surface and core antigens in peripheral blood mononuclear cell subsets by flow cytometry. J. Viral Hepat. 1994; 1: 39-44.
  7. Torbenson M., Thomas D.L. Occult hepatitis B. Lancet Infect. Dis. 2002; 2: 479-486
  8. Loriot M.A., Marcellin P., Walker F., Boyer N., Degott C., Randrianatoavina I., Benhamou J.P., Erlinger S. Persistence of hepatitis B virus DNA in serum and liver from patients with chronic hepatitis B after loss of HBsAg. J. Hepatol. 1997; 27: 251-258.
  9. Kwak M.S., Cho E.J., Jang E.S., Lee J.H., Yu S.J., Kim Y.J., Yoon J.H., Lee H.S. Predictors of HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients. Digestion 2011; 84(1): 23-28.
  10. Urbani S., Fagnoni F., Missale G., Franchini M. The role of anti-core antibody response in the detection of occult hepatitis B virus infection. Clin. Chem. Lab. Med. 2010; 48: 23-29.
  11. Hollinger F.B., Sood G. Occult hepatitis B virus infection: a covert operation. J. Viral. Hepat. 2010; 17: 1-15.
  12. Vitale F., Tramuto F., Orlando A., Vizzini G., Meli V., Cerame G., Mazzucco W., Virdone R., Palazzo U., Villafrate M.R., Tagger A., Romano N. Can the serological status of anti-HBc alone be considered a sentinel marker for detection of occult HBV infection? J. Med. Virol. 2008; 80: 577-582.
  13. Kupski C., Trasel F.R., Mazzoleni F., Winckler M.A., Bender A.L., Machado D.C., Schmitt V.M. Serologic and molecular profile of anti-HBc-positive blood bank donors in an area of low endemicity for HBV. Dig. Dis. Sci. 2008; 53: 1370-1374.
  14. Dickson R.C., Everhart J.E., Lake J.R., Wei Y., Seaberg E.C., Wiesner R.H., Zetterman R.K., Pruett T.L., Ishitani M.B., Hoofnagle J.H. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterohgy 1997; 113: 1668-1674.
  15. Raimondo G., Navarra G., Mondello S., Costantino L., Colloredo G., Cucinotta E. Occult hepatitis B virus in liver tissue of individuals without hepatic disease. J. Hepatol. 2008; 48: 743-746.
  16. Han Z., Liu Y., Pan J., Bi Y., Liu J., Zhou Y.H. Occult hepatitis B virus infection with positive hepatitis B e antigen. Clin. Chim. Acta 2015; 438(1): 266-268.
  17. Yuki N., Nagaoka T., Yamashiro M., Mochizuki K., Kaneko A., Yamamoto K., Omura M., Hikiji K., Kato M. Long-term histologic and virologic outcomes of acute self-limited hepatitis B. Hepatology (Baltimore, MD) 2003; 37: 1172-179. 18.
  18. de la Fuente R.A., Gutierrez M.L., Garcia-Samaniego J., Fernandez-Rodriguez C., Lledo J.L., Castellano G. Pathogenesis of occult chronic hepatitis B virus infection. World J. Gastroenterol. 2011; 17(12): 1543-1548.
  19. Ганина А.А. «Скрытая» ВГВ-инфекция среди доноров крови и лиц, относящихся к группам риска инфицирования. Автореф. дис. ... канд. биол. наук. М., 2009.
  20. Minuk G.Y., Sun D.F., Uhanova J., Zhang M., Caouette S., Nicolle L.E., Gutkin A., Doucette K., Martin B., Giulivi A. Occult hepatitis B virus infection in a North American community-based population. J. Hepatol. 2005; 42: 480-485.
  21. Kim S.M., Lee K.S., Park C.J., Lee J.Y., Kim K.H., Park J.Y., Lee J.H., Kim H.Y., Yoo J.Y., Jang M.K. Prevalence of occult HBV infection among subjects with normal serum ALT levels in Korea. J. Infect. 2007; 54:185-191.
  22. Hui C.K., Sun J., Au W.Y., Lie A.K., Yueng Y.H., Zhang H.Y. Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area. J. Hepatol. 2005; 42: 813-819.
  23. Doda V., Arora S., Kirtania T. Serological characterization of occult hepatitis B virus infection among blood donors in India. Transfus. Apher. Sci. 2014; 51(2): 162-167.
  24. Rios-Ocampo W.A., Cortes-Mancera F., Olarte J.C., Soto A., Navas M.C. Occult hepatitis B virus infection among blood donors in Colombia. J. Virol . 2014; 11: 206-217.
  25. Arababadi M.K., Hassanshahi G., Pourfathollah A.A., Zarandi E.R., Kennedy D. post-transfusion occult hepatitis b (OBI): a global challenge for blood recipients and health authorities. Hepat. Mon. 2011; 11(9): 714-718.
  26. Ярош Л.В. Эпидемиологическая характеристика HBsAg-мутантов и «скрытых» форм гепатита В среди различных групп населения. Автореф. дис.... канд. мед. наук. М., 2013.
  27. Raimondo G., Pollicino T., Cacciola I., Squadrito G. Occult hepatitis B virus infection. J. Hepatol. 2007; 46: 160-170.
  28. Torbenson M., Kannangai R., Astemborski J., Strathdee S.A., Vlahov D., Thomas D.L. High prevalence of occult hepatitis B in Baltimore injection drug users. Hepatology 2004; 39: 51-57.
  29. Toyoda H., Hayashi K., Murakami Y., Honda T., Katano Y., Nakano I., Goto H., Kumada T., Takamatsu J. Prevalence and clinical implications of occult hepatitis B viral infection in hemophilia patients in Japan. J. Med. Virol. 2004; 73:195-199.
  30. Saijo T., Joki N., Inishi Y., Muto M., Saijo M., Hase H. Occult Hepatitis B Virus Infection in Hemodialysis Patients in Japan. Ther. Apher. Dial. 2015; 19(2): 125-30.
  31. Kim S.M., Kim H.W., Lee J.E., Lee E.K., Shin H.D., SongI.H. Occult hepatitis B virus infection of hemodialysis patients: A cross-sectional study in a hepatitis B virus-endemic region. Hemodial. Int. 2015; 19(1): 66-71.
  32. Katayama K., Sato T., Son D.H., Yamada H., Tabuchi A., Komiya Y., Matsuo J., Nakashima A., Ohisa M., Akita T., Yorioka N., Miyakawa Y., Yoshizawa H., Tanaka J. Hepatitis B virus infection in hemodialysis patients in Japan: prevalence, incidence and occult HBV infection. Hepatol. Res. 2015; doi: 10.1111/hepr. 12492: 1-9.
  33. Bae E., Park C.H., Ki C.S., Kim S.J., Huh W., Oh H.Y., KangE.S. Prevalence and clinical significance of occult hepatitis B virus infection among renal transplant recipients in Korea. Scand. J. Infect. Dis. 2012; 44(10): 788-792.
  34. Squadrito G., Cacciola I., Alibrandi A., Pollicino T., Raimondo G. Impact of occult hepatitis B virus infection on the outcome of chronic hepatitis C. J. Hepatol. 2013; 59(4): 696-700.
  35. Shetty K., Hussain M., Nei L., Reddy K.R., Lok A.S. Prevalence and significance of occult hepatitis B in a liver transplant population with chronic hepatitis C. Liver Transpl. 2008; 14: 534-540.
  36. Raffa G., Maimone S., Cargnel A., Santantonio T., Antonucci G., Massari M. et al. Analysis of occult hepatitis B virus infection in liver tissue of HIV patients with chronic hepatitis C. AIDS 2007; 21: 2171-2175.
  37. Wong D.K., Huang F.Y., Lai C.L., Poon R.T., Seto W.K., Fung J. et al. Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. Hepatology 2011; 54: 829-836.
  38. Georgiadou S.P., Zachou K., Liaskos C., Gabeta S., Rigopoulou E.I., Dalekos G.N. Occult hepatitis B virus infection in patients with autoimmune liver diseases. Liver Int. 2009; 29: 434-442.
  39. Ferrari T.C., Xavier M.A., Vidigal P.V., Amaral N.S., Diniz P.A., Resende A.P., Miranda D.M., Faria A.C., Lima A.S., Faria L.C. Occult hepatitis B virus infection in liver transplant patients in a Brazilian referral center. Braz. J. Med. Biol. Res. 2014; 47(11): 990-994.
  40. Levrero M., Pollicino T., Petersen J., Belloni L., Raimondo G., Dandri M. Control of cccDNA function in hepatitis B virus infection. J. Hepatol. 2009; 51: 581-592.
  41. El C.M., Candotti D., Crowther R.A., Allain J.P. Impact of hepatitis B virus surface protein mutations on the diagnosis of occult hepatitis B virus infection. Hepatology 2010; 52: 1600-1610.
  42. Kim H., Lee S., Won Y.-S., Lee H., Kim B.J. Occult infection related hepatitis B surface antigen variants showing lowered secretion capacity. World J. Gastroenterol. 2015; 21(6): 1794- 1803.
  43. Vivekanandan P., Kannangai R., Ray S.C., Thomas D.L., Torbenson M. Comprehensive genetic and epigenetic analysis of occult hepatitis B from liver tissue samples. Clin. Infect. Dis. 2008; 46:1227-1236.
  44. Pollicino T., Amaddeo G., Restuccia A., Raffa G., Alibrandi A., Cutroneo G., Favaloro A., Maimone S., Squadrito G., Raimondo G. Impact of hepatitis B virus (HBV) preS/S genomic variability on HBV surface antigen and HBV DNA serum levels. Hepatology 2012; 56(2): 434-443.
  45. Zerbini A., Pilli M., Boni C., Fisicaro P., Penna A., Di Vincenzo P., Giuberti T., Orlandini A., Raffa G., Pollicino T., Raimondo G., Ferrari C., Missale G. The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection. Gastroenterology 2008; 134: 1470-1481.
  46. Kusumoto S., Tanaka Y., Mizokami M., Ueda R. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int. J. Hematol. 2009; 90: 13-23.
  47. Penna A., Artini M., Cavalli A., Levrero M., Bertoletti A., Pilli M., Chisari F.V., Rehermann B., Del Prete G., Fiaccadori
  48. F., Ferrari C. Long-lasting memory T cell responses following self-limited acute hepatitis B. J. Clin. Invest. 1996; 98:1185- 1194.
  49. Mason A.L., Xu L., Guo L., Kuhns M., Perrillo R.P. Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen. Hepatology 1998; 27: 1736-1742.
  50. Raimondo G., Caccamo G., Filomia R., Pollicino T. Occult HBV infection. Semin Immunopathol. 2013; 35: 39-52. 50.
  51. Cohen Stuart J.W., Velema M., Schuurman R., Boucher C.A., Hoepelman A.I. Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy. J. Med .Virol. 2009; 81: 441-445.
  52. Martin C.M., Welge J.A., Shire N.J., Shata M.T., Sherman K.E., Blackard J.T. Cytokine expression during chronic versus occult hepatitis B virus infection in HIV co-infected individuals. Cytokine 2009; 47: 194-198.
  53. Raimondo G., Cacciamo G., Saitta C. Hepatitis B virus and hepatitis C virus co-infection: additive players in chronic liver disease? Ann Hepatol. 2005; 4: 100-106.
  54. Bellecave P., Gouttenoire J., Gajer M., Brass V., KoutsoudakisG., Blum H.E., Bartenschlager R., Nassal M., MoradpourD. Hepatitis B and C virus coinfection: a novel model system reveals the absence of direct viral interference. Hepatology 2009; 50: 46-55.
  55. Ocana S., Casas M.L., Buhigas I., Lledo J.L. Diagnostic strategy for occult hepatitis B virus infection. World J. Gastroenterol. 2011;17(12): 1553-1557.
  56. Samal J., Kandpal M., Vivekanandan P. Molecular mechanisms underlying occult hepatitis B virus infection. Clin. Microbiol. Rev. 2012; 25: 142-163.
  57. Kwak M.S., Kim Y.J. Occult hepatitis B virus infection. World J. Hepatol. 2014; 6(12): 860-869.
  58. Allain J.P., Cox L. Challenges in hepatitis B detection among blood donors. Curr. Opin. Hematol. 2011; 18: 461-466.
  59. Allain J.P. Occult hepatitis B virus infection: implications in transfusion. Vox Sang. 2004; 86: 83-91.
  60. Liu C.J., Lo S.C., Kao J.H., Tseng P.T., Lai M.Y., Ni Y.H., Yeh S.H., Chen P.J., Chen D.S. Transmission of occult hepatitis B virus by transfusion to adult and pediatric recipients in Taiwan. J. Hepatol. 2006; 44: 39-46.
  61. Kwon C.I., Hwang S.G., Shin S.J., Chang S.W., Kim S.Y., Ko K.H., Hong S.P., Park P.W., Rim K.S., Kang M.S., Chung H.J., Hong S.P. Occult hepatitis B virus infection in pregnant woman and its clinical implication. Liver Int. 2008; 28: 667-674.
  62. Cheung C.K., Lo C.M., Man K., Lau G.K. Occult hepatitis B virus infection of donor and recipient origin after liver transplantation despite nucleoside analogue prophylaxis. Liver Transpl. 2010; 16: 1314-1323.
  63. Mahboobi N., Tabatabaei S.V., Blum H.E., Alavian S.M. Renal grafts from anti-hepatitis B core-positive donors: a quantitative review of the literature. Transpl. Infect. Dis. 2012; 14: 445-451.
  64. Samuel D., Forns X., Berenguer M., Trautwein C., Burroughs A., Rizzetto M., Trepo C. Report of the monothematic EASL conference on liver transplantation for viral hepatitis. J. Hepatol. 2006; 45: 127-143.
  65. Chazouilleres O., Mamish D., Kim M., Carey K., Ferrell L., Roberts J.P., Ascher N.L., Wright T.L. «Occult» hepatitis B virus as source of infection in liver transplant recipients. Lancet 1994; 343: 142-146.
  66. Cholongitas E., Papatheodoridis G.V., Burroughs A.K. Liver grafts from anti-hepatitis B core positive donors: a systematic review. J. Hepatol. 2010; 52: 272-279.
  67. Coffin C.S., Mulrooney-Cousins P.M., van Marle G., Roberts J.P., Michalak T.I., Terrault N.A. Hepatitis B virus quasispecies in hepatic and extrahepatic viral reservoirs in liver transplant recipients on prophylactic therapy. Liver Transpl. 2011; 17: 955-962.
  68. Loomba R., Rowley A., Wesley R., Liang T.J., Hoofnagle J.H., Pucino F., Csako G. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann. Intern. Med. 2008; 148: 519-528.
  69. Marzano A., Angelucci E., Andreone P., Brunetto M., Bruno R., Burra P., Caraceni P., Daniele B., Di Marco V., Fabrizi F., Fagiuoli S., Grossi P., Lampertico P., Meliconi R., Mangia A., Puoti M., Raimondo G., Smedile A. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis. 2007; 39: 397-408.
  70. Kamitsukasa H., Iri M., Tanaka A., Nagashima S., Takahashi M., Nishizawa T., Okamoto H. Spontaneous reactivation of hepatitis B virus (HBV) infection in patients with resolved or occult HBV infection. J. Med. Virol. 2015; 87(4): 589-600.
  71. Pei S.N., Chen C.H., Lee C.M., Wang M.C., Ma M.C., Hu T.H., Kuo C.Y. Reactivation of hepatitis B virus following rituximabbased regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann. Hematol. 2010; 89: 255-262.
  72. Yeo W., Chan T.C., Leung N.W., Lam W.Y., Mo F.K., Chu M.T., Chan H.L., Hui E.P., Lei K.I., Mok T.S., Chan P.K. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J. Clin. Oncol. 2009; 27: 605-611.
  73. Grewal J., Dellinger C.A., Yung W.K. Fatal reactivation of hepatitis B with temozolomide. N. Engl. J. Med. 2007; 356: 1591-1592.
  74. Hui C.K., Cheung W.W., Zhang H.Y., Au W.Y., Yueng Y.H., Leung A.Y., Luk J.M., Lie A.K., Kwong Y.L., Liang R., Lau G.K. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006; 131: 59-68.
  75. Ishiga K., Kawatani T., Suou T., Tajima F., Omura H., Idobe Y., Kawasaki H. Fulminant hepatitis type B after chemotherapy in a serologically negative hepatitis B virus carrier with acute myelogenous leukemia. Int. J. Hematol. 2001; 73: 115-118.
  76. Altfeld M., Rockstroh J.K., Addo M., Kupfer B., Pult I., WillH., Spengler U. Reactivation of hepatitis B in a long-term anti-HBs-positive patient with AIDS following lamivudine withdrawal. J. Hepatol. 1998; 29: 306-309.
  77. Persico E., De Renzo A., La Mura V., Bruno S., Masarone M., Torella R., Persico M. Occult hepatitis B virus infection in patients with non-Hodgkin lymphoma: the need for early diagnosis in anti-Hbc positive patients. Gut 2007; 56: 1470- 1471.
  78. Onozawa M., Hashino S., Izumiyama K., Kahata K., Chuma M., Mori A., Kondo T., Toyoshima N., Ota S., Kobayashi S., Hige S., Toubai T., Tanaka J., Imamura M., Asaka M. Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation 2005; 79: 616-619.
  79. Vigano M., Vener C., Lampertico P., Annaloro C., Pichoud C., Zoulim F., Facchetti F., Poli F., Scalamogna M., Deliliers G.L., Colombo M. Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT. Bone Marrow Transplant. 2011; 46: 125-131.
  80. Yeo W., Johnson P.J. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006; 43: 209-220.
  81. Sagnelli E., Pisaturo M., Martini S., Filippini P., Sagnelli C., Coppola N. Clinical impact of occult hepatitis B virus infection in immunosuppressed patients. World J. Hepatol. 2014; 6(6): 384-393.
  82. Coppola N., Tonziello G., Pisaturo M., Messina V., Guastafierro S., Fiore M., Iodice V., Sagnelli C., Stanzione M., Capoluongo N., Pasquale G., Sagnelli E. Reactivation of overt and occult hepatitis B infection in various immunosuppressive settings. J. Med. Virol. 2011; 83: 1909-1916.
  83. Mastroianni C.M., Lichtner M., Citton R., Del Borgo C., Rago A., Martini H., Cimino G., Vullo V. Current trends in management of hepatitis B virus reactivation in the biologic therapy era. World J. Gastroenterol. 2011; 17: 3881-3887.
  84. Squadrito G., Spinella R., Raimondo G. The clinical significance of occult HBV infection. Ann. Gastroenterol. 2014; 27: 15-19.
  85. Hui C.K., Cheung W.W., Au W.Y., Lie A.K., Zhang H.Y., Yueng Y.H., Wong B.C., Leung N., Kwong Y.L., Liang R., Lau G.K. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut 2005; 54: 1597- 1603.
  86. Dai M.S., Chao T.Y., Kao W.Y., Shyu R.Y., Liu T.M. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann. Hematol. 2004; 83: 769-774.
  87. Lledó J.L., Fernández C., Gutiérrez M.L., Ocana S. Management of occult hepatitis B virus infection: an update Обычныйfor the clinician. World J. Gastroenterol. 2011; 17(12): 1563-1568.
  88. Lee Y.H., Bae S.C., Song G.G. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy. Clin. Exp. Rheumatol. 2013; 31: 118-121.
  89. Raimondo G., Pollicino T., Squadrito G. What is the clinical impact of occult hepatitis B virus infection? Lancet 2005; 365: 638-640.
  90. Covolo L., Pollicino T., Raimondo G., Donato F. Occult hepatitis B virus and the risk for chronic liver disease: a meta-analysis. Dig. Liver Dis. 2013; 45: 238-244.
  91. Toniutto P., Minisini R., Fabris C., De F.T., Marangoni F., Burlone M., Avellini C., Bitetto D., Fornasiere E., Fumolo E., Baccarani U., Pirisi M. Occult hepatitis B virus infection in liver transplant recipients with recurrent hepatitis C: relationship with donor age and fibrosis progression. Clin. Transplant. 2009; 23:184-190.
  92. Angelico M., Nardi A., Marianelli T., Caccamo L., Romagnoli R., Tisone G., Pinna A.D., Avolio A.W., Fagiuoli S., Burra P., Strazzabosco M., Costa A.N. Hepatitis B-core antibody positive donors in liver transplantation and their impact on graft survival: evidence from the Liver Match cohort study. J . Hepatol. 2013; 58: 715-723.
  93. Pollicino T., Saitta C., Raimondo G. Hepatocellular carcinoma: the point of view of the hepatitis B virus. Carcinogenesis 2011; 32: 1122-1132.
  94. Shi Y., Wu Y.H., Wu W., Zhang W.J., Yang J., Chen Z. Association between occult hepatitis B infection and the risk of hepatocellular carcinoma: a meta-analysis. Liver Int. 2012; 32: 231-240.
  95. Fwu C.W., Chien Y.C., Kirk G.D., Nelson K.E., You S.L., Kuo H.S., Feinleib M., Chen C.J. Hepatitis B virus infection and hepatocellular carcinoma among parous Taiwanese women: nationwide cohort study. J. Natl. Cancer Inst. 2009; 101: 1019-1027.
  96. Miura Y., Shibuya A., Adachi S., Takeuchi A., Tsuchihashi T., Nakazawa T., Saigenji K. Occult hepatitis B virus infection as a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C in whom viral eradication fails. Hepatol. Res. 2008; 38: 546-556.
  97. Ikeda K., Kobayashi M., Someya T., Saitoh S., Hosaka T., Akuta N., Suzuki F., Suzuki Y., Arase Y., Kumada H. Occult hepatitis B virus infection increases hepatocellular carcinogenesis by eight times in patients with non-B, non-C liver cirrhosis: a cohort study. J. Viral Hepat. 2009; 16: 437-443. 97.
  98. Di Bisceglie A.M. Hepatitis B and hepatocellular carcinoma. Hepatology 2009; 49: 56-60.
  99. Fwu C.W., Chien Y.C., You S.L., Nelson K.E., KirkG.D., Kuo H.S., Feinleib M., Chen C.J. Hepatitis B virus infection and risk of intrahepatic cholangiocarcinoma and non-Hodgkin lymphoma: a cohort study of parous women in Taiwan. Hepatology 2011; 53: 1217-1225.
  100. Marcucci F., Mele A., Spada E., Candido A., Bianco E., Pulsoni A., Chionne P., Madonna E., Cotichini R., Barbui A., De Renzo A., Dore F., Iannitto E., Liso V., Martino B., Montanaro M., Pagano L., Musto P., Rapicetta M. High prevalence of hepatitis B virus infection in B-cell non-Hodgkin's lymphoma. Haematologica 2006; 91: 554-557.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies